Beta Bionics (BBNX) CCO Mark Hopman Sells 35,994 Shares

What Happened

Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), sold 35,994 shares on September 9, 2026 at $18.46 per share, generating proceeds of $664,550. The sale was executed pursuant to a Rule 10b5‑1 trading plan and is a disposition (sale), not a purchase.

Key Details

• Transaction date and price: 2026-09-09, 35,994 shares at $18.46 each.
• Total proceeds: $664,550.
• Shares owned after the sale: 88,033 shares (as corrected in the amended filing).
• Footnotes:
  • The shares were sold under a Rule 10b5‑1 plan adopted June 10, 2026.
  • The initial Form 4 filed on Sept 10, 2026 misreported the number of shares disposed; this Form 4 (amendment) corrects that error.
• Filing status: This is an amended Form 4 correcting an earlier filing. The original Form 4 (filed Sept 10) contained an incorrect share count; the amendment clarifies the correct disposal amount and resulting holdings.

Context

• Sales under pre-established 10b5‑1 plans are common and generally indicate planned, rule-compliant dispositions rather than real-time trading on material company developments.
• For retail investors, purchases are typically more informative about insider confidence; this transaction is a routine sale under a trading plan and should be interpreted as such.